drugset / Trial / NCT01259050

Safety Study of High Doses of Zinc in ALS Patients

NCT01259050

Phase 1/2 Completed 10 enrolled Phoenix Neurological Associates, LTD
RandomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the safety of Zinc given at 90mg/d in conjunction with 2mg/d of copper in ALS patients.

Timeline

Start
2010-10
Primary completion
2012-01
Completion
2012-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Zinc Sulfate Unknown 90 mg
Background Copper Unknown 1 mg